On the persitance of compound to target miss-mappings
Christopher Southan · 2012
The first part of this story is - sort of - our fault. Once upon a time, we wuz digging novel human proteases out of EST data and filing patents as fast as we could clone 'em (which wasn't that fast in fact). One of these happened to be homologue of a bacterial serine beta lactamase so we duly filed it as WO9957286 but, because it did not look like the next big drug project target we were permitted to publish.